MiMedx Group, Inc.
NASDAQ•MDXG
CEO: Mr. Joseph H. Capper
セクター: Healthcare
業種: Biotechnology
上場日: 2008-02-12
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.
連絡先情報
時価総額
$650.72M
PER (TTM)
13.3
17.9
配当利回り
--
52週高値
$8.13
52週安値
$4.34
52週レンジ
順位54Top 78.1%
2.7
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2.7 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$118.10M+0.00%
直近4四半期の推移
EPS
$0.10+0.00%
直近4四半期の推移
フリーCF
$24.58M+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Net Sales Increased 20.0% Full year 2025 net sales reached $418.6M, reflecting 20.0% growth driven by Wound and Surgical segments.
Income From Operations Grew Net income from continuing operations totaled $48.6M in 2025, marking a 15.7% increase over the prior year.
Expanded Product Portfolio Offerings Secured exclusive distribution for RegenKit-Wound Gel and launched EPIXPRESS, broadening advanced wound care options.
Strong Cash Position Maintained Cash and equivalents stood at $166.1M on December 31, 2025, supporting liquidity needs for the next twelve months.
リスク要因
Medicare Reimbursement Rate Cap CMS capped skin substitute reimbursement at $127.14/cm² starting January 2026, creating a significant 2026 sales headwind.
AXIOFILL FDA Classification Lawsuit Ongoing legal proceedings regarding AXIOFILL classification may result in loss of marketing ability if determination is unfavorable.
Intense Competition and Pricing Pressure Highly competitive evolving field faces pressure from established processors and new entrants, impacting pricing realization.
Dependence on Tissue Donor Supply Commercial success relies on availability of human donor tissue; supply disruptions could severely affect manufacturing capabilities.
見通し
Prioritize Product Innovation Growth Strategy focuses on innovating portfolio, launching EPIXPRESS, and expanding internationally, especially targeting Japan market growth.
Expand Surgical Footprint Programs Develop programs to penetrate surgical settings by leveraging existing evidence and investing in new surgical product adoption.
Share Repurchase Plan Authorized Board authorized up to $100.0M share repurchase plan through February 2028, focusing capital deployment strategically.
Enhance Customer Intimacy Efforts Implement MIMEDX Connect portal to streamline ordering and payment processing, aiming to lower customer turnover rates.
同業比較
売上高 (TTM)
$418.63M
$414.76M
$234.60M
粗利益率 (最新四半期)
199.8%
102.3%
100.0%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| DNTH | $2.82B | 0.0 | 0.0% | 0.3% |
| SNDX | $2.07B | -7.1 | -206.6% | 65.4% |
| TNGX | $2.01B | -19.8 | -50.3% | 8.4% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
10.2%
安定成長
4四半期純利益CAGR
29.3%
収益性の大幅な改善
キャッシュフロー安定性
100%
優れたキャッシュフローの実績
深度リサーチ
次回決算:2026年4月28日
EPS:-
|売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし